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Abstract
Background: In 2010, Me´decins Sans Frontie`res (MSF) discovered extensive lead poisoning impacting several thousand
children in rural northern Nigeria. An estimated 400 fatalities had occurred over 3 mo. The US Centers for Disease Control
and Prevention (CDC) confirmed widespread contamination from lead-rich ore being processed for gold, and environmental
management was begun. MSF commenced a medical management programme that included treatment with the oral
chelating agent 2,3-dimercaptosuccinic acid (DMSA, succimer). Here we describe and evaluate the changes in venous blood
lead level (VBLL) associated with DMSA treatment in the largest cohort of children #5 y of age with severe paediatric lead
intoxication reported to date to our knowledge.
Methods and Findings: In a retrospective analysis of programme data, we describe change in VBLL after DMSA treatment courses
in a cohort of 1,156 children#5 y of age who underwent between one and 15 courses of chelation treatment. Courses of DMSA of
19 or 28 d duration administered to children with VBLL $ 45 mg/dl were included. Impact of DMSA was calculated as end-course
VBLL as a percentage of pre-course VBLL (ECP). Mixed model regression with nested random effects was used to evaluate the
relative associations of covariates with ECP. Of 3,180 treatment courses administered, 36% and 6% of courses commenced with
VBLL$ 80 mg/dl and$ 120 mg/dl, respectively. Overall mean ECP was 74.5% (95% CI 69.7%–79.7%); among 159 inpatient courses,
ECP was 47.7% (95% CI 39.7%–57.3%). ECP after 19-d courses (n=2,262) was lower in older children, first-ever courses, courses with
a longer interval since a previous course, courses withmore directly observed doses, and courses with higher pre-course VBLLs. Low
haemoglobin was associated with higher ECP. Twenty children aged #5 y who commenced chelation died during the period
studied, with lead poisoning a primary factor in six deaths. Monitoring of alanine transaminase (ALT), creatinine, and full blood count
revealed moderate ALT elevation in ,2.5% of courses. No clinically severe adverse drug effects were observed, and no laboratory
findings required discontinuation of treatment. Limitations include that this was a retrospective analysis of clinical data, and
unmeasured variables related to environmental exposures could not be accounted for.
Conclusions: Oral DMSA was a pharmacodynamically effective chelating agent for the treatment of severe childhood lead
poisoning in a resource-limited setting. Re-exposure to lead, despite efforts to remediate the environment, and non-
adherence may have influenced the impact of outpatient treatment.
Please see later in the article for the Editors’ Summary.
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Introduction
Lead poisoning is a major and likely under-reported global
health problem. There are many widely prevalent sources of lead
exposure: lead-acid battery maanufacturing and recycling [1];
mining, smelting, and refining of lead and other ores [2];
traditional medicines [3]; residential paint [4]; ceramic glaze and
artisanal pottery [5]; ammunition; and metal alloys or pigments
used in the fabrication or coating of children’s toys and jewellery.
Most of these sources are poorly regulated in resource-poor
countries.
Lead poisoning causes a continuum of effects ranging from
subtle deficits in neurocognitive function to hypertension, cardio-
vascular disease, anaemia [6], renal dysfunction [7], and acute life-
threatening encephalopathy [8,9]. Lead-related child deaths in US
cities in the 1950s and 1960s were frequent [10,11] and were
primarily related to lead paint ingestion. Chisolm and Harrison
reported 36 cases of severe lead encephalopathy between 1954 and
1956 [12], and 38 cases were reported by Greengard et al.
between 1959 and 1963 [13]. Fatal lead poisoning in resource-rich
countries has rarely been reported in recent decades. The last
death directly attributed to lead toxicity in the US occurred in
2006 in a child who swallowed a metallic charm [14]. However, in
resource-poor countries, outbreaks are being reported with
increasing frequency. An outbreak in Senegal in 2007 associated
with informal lead-acid battery recycling resulted in a mean
venous blood lead level (VBLL) of 130 mg/dl in 50 children, with
at least 18 deaths [1]. In China, environmental exposure to
industrial emissions has been linked to lead poisoning—though
with comparatively low lead levels [15] and with no detailed
reports of encephalopathic children.
In March 2010, the medical humanitarian aid organisation
Me´decins Sans Frontie`res (MSF) responded to reports of unusual
mortality in children #5 y old in Zamfara State, northern Nigeria
[16,17]. Over a 2-mo period until 17 May 2010, nearly 300
children aged #5 y presented in four villages with intractable
seizures of unknown aetiology, with a mortality of 48%. Before
this period, many other children were reported to have died; the
total number of deaths has been estimated at around 400.
Recently expanded artisanal gold mining, using rudimentary
processing techniques with ore that was heavily lead-laden, had
resulted in the release of large amounts of lead dust. In May
2010, MSF and the US Centers for Disease Control and
Prevention (CDC) identified widespread environmental lead
contamination. This was fully characterised by TerraGraphics
Environmental Engineering in conjunction with other agencies,
which recorded surface soil concentrations within the affected
villages of .10% lead (.100,000 ppm) [18]. The screening level
set by the US Environmental Protection Agency above which
remediation should usually occur in areas where children play is
400 ppm [19]. TerraGraphics Environmental Engineering, the
Zamfara state government, and the Blacksmith Institute initiated
environmental remediation after mining activities were moved
some kilometres from village borders. Health promotion
addressed ways to prevent further lead exposure.
Although the therapeutic efficacy of lead chelation in reducing
morbidity and mortality has never been demonstrated in a
randomised controlled trial [20], a net overall reduction in blood
lead is thought to be beneficial in severe intoxication by decreasing
the potential for ongoing translocation of lead from blood to brain.
MSF started a lead poisoning treatment programme using
dimercaptosuccinic acid (DMSA, succimer) chelation in June
2010. By the end of 2012, MSF had screened 2,912 children aged
#5 y in seven remediated villages; 94% of the children had VBLLs
above 10 mg/dl (range 3–708) [16,19]. The programme is
ongoing, and more than 15,000 treatment courses have been
commenced for children, with up to 34 courses per child—this
paper examines data from the first year of the response.
Chelating agents used to treat lead poisoning include intrave-
nous (IV) calcium disodium versenate (CaNa2EDTA), intramus-
cular dimercaprol, and oral DMSA. DMSA, a less toxic, water-
soluble analogue of dimercaprol, was first introduced as a possible
antidote to lead poisoning in the late 1950s [21,22,23]. In several
studies, DMSA has been observed to be an effective oral chelator
of lead with a low incidence of major adverse events
[24,25,26,27,28]. It has typically not been used as a sole
pharmaceutical agent in patients with overt lead encephalopathy
because of theoretical concerns that it might have less utility than
parenteral CaNa2EDTA in reducing high VBLL [20,25]. How-
ever, the only comprehensive review available of CaNa2EDTA
versus DMSA did not find evidence for superiority of one chelator
over the other, and concluded that DMSA could be considered in
circumstances where oral therapy is preferable [29].
Although removal from lead exposure remains the single most
important intervention for the overexposed child and will usually
be followed by a decline in blood lead, the accelerated reduction
induced by chelation is recommended at VBLL $ 45 mg/dl to
avert potential progression to encephalopathy [30,31]. DMSA has
been the recommended first-line chelation agent for non-
encephalopathic patients with VBLL $ 45 mg/dl since 1995
[31]. While there are regimen recommendations, there remains
some uncertainty regarding optimal dosing, length of course,
length of time between courses, and adverse effects, particularly in
severe poisoning, as reports of treatment of sizeable cohorts of
severely lead-poisoned children are rare [24,32]. In the US in
2010, only 347 (0.009%) of almost 4 million children #5 y
screened had VBLL $ 45 mg/dl, and of these only 51 (0.001%)
had VBLL $ 70 mg/dl [33]. CaNa2EDTA has generally been
recommended as the first-line regimen for children with VBLL .
70 mg/dl, and published reports of the use of DMSA in children
with VBLL . 100 mg/dl are limited [34,35]. The sudden
discovery of more than 1,000 active cases of moderate and severe
childhood lead poisoning in rural villages in northern Nigeria
required an approach to chelation suitable for this remote,
resource-limited setting where safe, sterile administration of
individualised dosages of IV CaNa2EDTA was not feasible.
DMSA alone was therefore used, given orally in conscious
children and via nasogastric tube in encephalopathic patients.
Once the project was well-established, IV CaNa2EDTA was
administered to encephalopathic children.
In a retrospective analysis of clinical data from a cohort of more
than 1,000 lead-poisoned children in rural Zamfara, Nigeria, we
evaluated the changes in VBLL after oral chelation treatment with
DMSA and the occurrence of adverse drug effects associated with
DMSA treatment. Using regression models in the largest such
cohort of chelated children to our knowledge reported to date, we
examined the relative associations of different dose regimens and
other covariates with the magnitude of blood lead reduction
achieved by a course of chelation treatment.
Methods
Ethics Statement
This study met the standards set by the independent MSF
Ethics Review Board for retrospective analyses of routinely
collected programmatic data [36]. These standards include, but
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are not limited to, assurances of confidentiality, involvement of
local partners, and minimal harm to patients. Caregivers were
informed that routine data were being collected for clinical care
and could be used anonymised for programme monitoring and
increasing knowledge about lead poisoning. Coded identification
numbers were used, and personal identifiers and all unnecessary
data were removed from the dataset. Review of anonymous,
routinely collected programmatic data does not constitute research
under the Nigerian National Health Research Ethics Committee
guidelines. CDC involvement did not require Human Subjects
Review as CDC personnel were not involved in treating patients.
Chelation Protocol
The DMSA protocol in Zamfara aimed to deliver effective
chelation that was acceptable to the community and appropriate
to the challenging logistical context. If initial VBLL was $ 45 mg/
dl, children were treated with oral DMSA (Chemet, Lundbeck;
Succicaptal, Serb Laboratories). The contents of the DMSA
capsules were mixed with Plumpy’Nut (therapeutic food paste,
Nutriset) or milk for infants, or sprinkled on honey for older
children. For obtunded encephalopathic children, the contents of
the capsules were mixed with water, and the slurry was
administered by nasogastric tube (n= 14/3,180 [0.44%] chelation
courses included in analysis of end-course VBLL as a percentage
of pre-course VBLL [ECP]; n= 12/2,000 [0.6%] courses
excluded from ECP analysis).
Children were initially treated in June and July 2010 with 28-d
DMSA 10 mg/kg twice daily (BD), based on the protocol used
during the WHO- and CDC-supported intervention for a lead
poisoning outbreak in Kosovo [2,37]. Subsequently, most patients
were chelated using repeated 19-d DMSA treatment schedules
based on the US Food and Drug Administration’s approved drug
labelling. Each dose of DMSA was rounded to 100 mg (patient
weight ,15 kg) or 200 mg (15–24 kg) for ease of administration
(Figure 1). Because of the severity of their lead intoxication,
children with pre-course VBLL $ 120 mg/dl were treated with
10 mg/kg thrice daily (TDS) for the full 19 d. A minimum of 2 wk
between courses is recommended unless blood lead levels indicate
the need for more prompt treatment [35], so the VBLL measured
at the end of each course determined the timing of the next course
or VBLL test. All children received identical weight-based
supplementation with zinc sulphate, calcium carbonate, iron
sulphate, and folic acid (Table 1). Several minor revisions of the
protocol that streamlined the treatment and blood test regimen
and minimised burdens on patients and caretakers were under-
taken following an MSF expert advisory group’s interim analysis of
blood lead trends during courses of chelation. Box 1 describes the
revision process, Box 2 summarises key revisions, and Table 2
gives protocol details. All of the DMSA regimens have been used
previously in clinical trials and clinical toxicology practice
[26,27,38,39,40].
In hospital, all doses were directly observed (directly observed
therapy [DOT]); thus, inpatient location is a proxy for full
medication adherence and limited opportunity for further lead
exposure. Village environmental remediation commenced concur-
rent with the first inpatient courses, so for later courses patients were
hospitalised only if their village was yet to be remediated, or if they
were severely ill. Once a village’s environmental lead remediation
was completed, non-encephalopathic children were treated as
outpatients, initially with one of the two or three daily doses of
DMSA directly observed during a clinic visit. Several months later,
in response to a growing caseload and the request of parents, only
one dose on alternate days was directly observed at the clinic
(Table 2); other doses were administered by parents or guardians in
the home. The reduced frequency of DOT therefore applied to all
children on outpatient treatment and was due to the number of days
per week that the clinic operated, not to VBLL or clinical status.
Inclusions
All children aged #5 y from contaminated villages where
remediation was taking place were offered screening. Although all
residents of the contaminated villages were considered to have
elevated lead exposure, personnel and financial constraints
resulted in the chelation protocol being targeted to children #5
Figure 1. Representation of actual DMSA dose received by
weight with rounding of 100-mg tablets.
doi:10.1371/journal.pmed.1001739.g001
Table 1. Supplements to be provided throughout the
chelation course and 2 wk after ceasing treatment.
Supplement Recipient Quantity
Vitamin C All children 250 mg BD
Calcium (calcium carbonate) ,1 y 250 mg OD
1–3 y 500 mg OD
4–8 y 750 mg OD
Multivitamin All children 1 tab OD
Zinc (zinc sulphate) ,10 kg 5 mg OD
10–25 kg 10 mg OD
.25 kg 20 mg OD
Iron (tablets of ferrous
sulphate 60 mg + folic acid 0.4 mg)
Hb . 120 g/l
,16 kg J tab OD
Hb 110–120 g/l
,16 kg K tab OD
16–20 kg 1 tab OD
.20 kg 1K tab OD
Hb , 110* g/l
,12 kg K tab OD
12–20 kg 1 tab OD
.20 kg 1K tab OD
*Dose halved for first 2 d.
OD, once daily; tab, tablet.
doi:10.1371/journal.pmed.1001739.t001
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16–30 kg K tab OD
.30 kg 1 tab OD
y of age, the only subgroup in which serious morbidity and
mortality had been identified. For statistical analysis, only
completed courses of DMSA of 19 or 28 d started between 1
June 2010 and 30 June 2011 with valid pre- and end-course
VBLLs recorded (defined below) were included (Figure 2). Except
for analysis of overall VBLL decrease per child over the entire
period, 5-d DMSA courses (Table 2) were excluded. Included
chelation courses were administered to 1,156 children, 856 (74%)
of whom were included in a report on association of VBLL with
neurological features in 972 children [16].
Testing
Venepuncture was performed after cleaning the skin with
soapy water to minimise lead dust contamination. VBLL was
measured using the LeadCare II (Magellan) point-of-care
analyser according to manufacturer protocols. For samples with
lead levels .65 mg/dl, the upper quantification limit of the
device, a blood dilution method utilising donor blood with lead
concentration ,3.0 mg/dl [41] was developed and implemented
on 20 July 2010. Exclusion of courses with VBLL tests conducted
before the dilution protocol was finalised did not substantially
alter the results of regression modelling; thus, blood samples
obtained at all points in the study period were retained. Monthly
quality control was provided by the CDC using inductively
coupled plasma mass spectrometry (ICPMS): point-of-care values
of 120 clinical samples (including 15 samples requiring dilution in
the field laboratory) were on average 4.0 mg/dl lower than
ICPMS values (limits of agreement [42] [two standard deviations]
219.7 to +11.7 mg/dl).
Haemoglobin was measured with a HemoCue Hb 301 point-of-care
testing system prior to 22 November 2010 and with a Sysmex KX-21N
Automated Hematology Analyzer from this date. Creatinine and
alanine transaminase (ALT) were measured on a HumaLyzer 2000
(Human Gesellschaft fu¨r Biochemica und Diagnostica). White blood
Box 1. Process for Zamfara DMSA Protocol
Revision
(1) An expert advisory group* was convened by MSF,
comprising non-MSF medical toxicologists and public
health professionals with previous experience managing
lead poisoning, to guide MSF in building the chelation
programme.
(2) As the expert group was convened, MSF started
emergency chelation with 28-d BD dosing as per Kosovo
and Boston precedents [2].
(3) After the evidence base was reviewed by the expert
group, early adjustments to the protocol were made to
accord with dominant international practice (treatment
duration reduced from 28 to 19 d).
(4) Further adjustments were made based on the following:
N Feedback that was encouraged from programme
staff and patients (e.g., patients finding frequency of
tests or visits unacceptable, raising compliance
challenges).
N Regular review by programme medical staff for
possible areas for streamlining.
N Alterations requested by programme team.
N Review of Zamfara data by senior epidemiologist
(e.g., to determine whether lengthening chelation-
free periods was likely to put children at risk of VBLLs
rising to levels that might cause encephalopathy).
(5) Proposals for revision were prepared by the pro-
gramme advisor, consultant toxicologist, and epidemiolo-
gist for the expert group including risk analysis and
supporting data.
(6) Proposals were discussed with expert group by
teleconference and email to achieve consensus based on
literature review and expert opinion.
(7) Agreed revision implemented.
(8) Impact of revision monitored by field team and
headquarters support team.
*The expert advisory group comprised the non-MSF-
affiliated authors of this paper.
Box 2. Key Adaptations of Zamfara DMSA
Protocol{
July 2010
N Length of course reduced from 28 to 19 d to accord
with dominant international practice [25].
N Daily dose: 20 mg/kg/d increased to 30 mg/kg/d
with review on day 7 of course. Patients continued
on 30 mg/kg/d if day 7 VBLL $ 65 mg/dl, otherwise
decreased to 20 mg/kg/d till end of course.
N Outpatient daily DOT started via outreach clinics for
those from remediated villages.
N Next course started immediately if end-course VBLL
$ 65 mg/dl (previously 2-wk remobilisation interval
with any end-course VBLL).
October 2010
N Stopped day 7 VBLL and biochemical tests based on
ability to predict outcome at end of treatment from initial
VBLL, lack of toxicity concerns (ALT and creatinine), and
potential to improve community acceptance.
November 2010
N IV CaNa2EDTA introduced for chelation of enceph-
alopathic children.
N Moved to alternate-day DOT in outpatient clinics.
March 2011
N Lengthened chelation-free period dependent on
VBLL at end of course.
N 5-d courses of 30 mg/kg/d introduced for those with
VBLL of 45–64 mg/dl [24].
N 19-d courses of 30 mg/kg/d for 5 d, followed by
30 mg/kg/d if a first-ever course or if day 0 VBLL $
120 mg/dl, otherwise 20 mg/kg/d, for a further 14 d.
Note: 20 mg/kg/d and 30 mg/kg/d were both approxi-
mate and were actually rounded to 100 mg or 200 mg per
dose depending on weight.
{ For details of protocol see Table 2.
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cells (manual count prior to 22 November 2010, Sysmex KX-21N
Automated Hematology Analyzer thereafter) and neutrophils (from 22
November 2010, Sysmex KX-21N Automated Hematology Analyzer)
were also measured (white blood cell count was used to calculate
absolute neutrophil count from percent), although less consistently
because of operational constraints. A sensitivity analysis including a
pre-/post-change variable in the main regression model determined
that regression analyses were unchanged by the switch in analytical
method for haemoglobin. Clinical data were routinely entered into an
electronic database specifically designed to support patient care and
programme management through automated lists of protocol-dictated
actions, test result alerts, and detailed reports (Microsoft Excel 2007).
Adverse events were systematically monitored in that full blood
count, creatinine, and ALT were checked regularly at the beginning
and end of each course of chelation. Analysis included the
completed courses of chelation in the study database. Anecdotal
severe adverse events are reported here; minor clinical events (e.g.,
diarrhoea) were not recorded.
Definitions
A complete course of DMSA was defined as .60% of days of
doses being dispensed. ‘‘Pre-chelation VBLL’’ means first-ever
VBLL (chelation naı¨ve). ‘‘Pre-course VBLL’’ (‘‘day 0’’) means a
VBLL obtained up to 14 d before the course commenced, used to
dictate the length and dosing for an individual course. The ‘‘end-
course VBLL’’ was obtained from #2 d before to #10 d after the
end of treatment. Age at time of VBLL was categorised as 0 to ,6
mo, 6 to ,12 mo, 1 to ,2 y, 2 to ,3 y, and 3 to 5 y [43].
Haematological and biochemical parameters were categorised
as follows: haemoglobin as low (,100 g/l if ,2 y old; ,110 g/l if
2–5 y), high (.130 g/l if,2 y;.140 g/l if 2–5 y), or normal; ALT
as normal (0–42 U/l), mildly elevated (42.1–100 U/l), moderately
elevated (100.1–1,000 U/l), or severely elevated (.1,000 U/l);
creatinine as low (,44 mmol/l), high (.97 mmol/l), or normal;
neutrophil count as normal (.1.56109/l) or as mild (1.0–
1.56109/l), moderate (0.5–0.996109/l), or severe neutropenia
(,0.56109/l) [44].
Table 2. Developments in chelation protocol.
Development Protocol Revision Number
1 2 3 4 5*
Date commenced 01 Jun 2010 10 Jul 2010 01 Oct 2010 12 Nov 2010 29 Mar 2011
VBLL at which
treatment starts
$45 $45 $45 $45 $45 (unless end-course
result)
CaNa2EDTA available No No No 5 d course
(encephalopathic children)
Same as 4
Duration of DMSA course 28 d 19 d 19 d 19 d 19 d or 5 d
Dosing 28 d BD 7 d TDS + (12 d
BD or 12 d TDS)
Same as 2 Same as 2 5 d TDS + (14 d BD or 14 d
TDS or end)
VBLL tests used for
differential dosing
NA—no VBLL-
based dosing
Day-7 VBLL (at
threshold $ 65,
continue TDS)
Day-0 VBLL (at
threshold $ 120,
19-d TDS) (day-7
VBLL test eliminated)
Same as 3 Day-0 VBLL (threshold $
120); course $2, also Day-
0 VBLL (threshold ,65 for
5-d course)
Frequency of DOT
(non-DOT doses
administered by
caretaker)
All inpatient,
full DOT
Inpatient until late
July 2010, then daily
outpatient DOT (one
dose observed)
Daily outpatient DOT,
transition to alternate-
day outpatient DOT in
November 2010
Alternate-day
outpatient DOT
Same as 4
Protocol at end
of a course
Immediate retreatment No immediate
retreatment
End-course
VBLL $ 65
Same as 2 Same as 2 End-course VBLL $ 80
Re-test in 2 wk All End-course
VBLL ,65
Same as 2 Same as 2 End-course VBLL $ 65 and
,80
Re-test in 4 wk NA NA NA NA End-course VBLL $ 45 and
,65
Protocol with pre-
treatment screen or
post-chelation follow-up
VBLL test
Re-test in 2 wk VBLL $ 25 and ,45 Same as 1 Same as 1 NA NA
Re-test in 4 wk VBLL $ 20 and ,25 Same as 1 Same as 1 VBLL $ 35 and ,45 VBLL $ 30 and ,45
Re-test in 2 mo VBLL $ 15 and ,20 Same as 1 Same as 1 VBLL $ 20 and ,35 VBLL $ 20 and ,30
Re-test in 3 mo VBLL $ 10 and ,15 Same as 1 Same as 1 VBLL $ 10 and ,20 NA
Re-test in 6 mo NA NA NA NA VBLL $ 10 and ,20
Discharge VBLL ,10 Same as 1 Same as 1 Same as 1 Same as 1
*Flow-chart of protocol 5 provided in Figures S1–S3. VBLL units are micrograms per decilitre.
NA, not applicable.
doi:10.1371/journal.pmed.1001739.t002
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‘‘Rebound’’ refers to the rise in VBLL that may occur in the
days to weeks after a chelation-related reduction in VBLL.
Rebound typically reflects the internal movement of lead stored in
the bone and soft tissue compartments back into the blood
following a chelation episode. However, re-exposure to external
sources of lead after cessation of chelation may also influence the
magnitude of rebound that is recorded.
‘‘DMSA dose regimen’’ refers to the number of doses per day
and number of days of each regimen, while ‘‘DMSA administra-
tion method’’ refers to whether the dose was administered in
hospital or in the outpatient clinic/at home, and the frequency of
direct observation.
Analysis
We report the association between DMSA chelation and VBLL;
clinical outcomes will be reported separately. The primary
outcome variable was in line with that used in other studies
[24,25,26,27], defined here as end-course VBLL as a percentage
of pre-course VBLL (ECP):
ECP= (end-course VBLL/pre-course VBLL) 6 100% (1)
Thus, an ECP ,100% indicates a net decline in VBLL; ECP .
100% indicates that VBLL increased. Since a key goal of chelation
treatment is to reduce VBLL, a lower value of ECP is desirable.
Geometric means of ECP values for the relevant subset of courses
were calculated by fitting a mixed model containing only a
constant term using nested random effects (village, patient) to
account for repeated measurements in the same individual over
multiple treatment courses. The natural logarithm of ECP was the
dependant variable, and the exponential of coefficients and the
95% CIs were calculated.
Rebound was quantified as the percentage change between the
end-course and subsequent VBLL where there was no adminis-
tration of DMSA in the interim.
For clinical correlation, as a secondary outcome, absolute
increase or decrease of end-course VBLL compared to pre-course
VBLL was calculated, with arithmetic means and 95% CIs
reported since these data were normally distributed, nested by
village and patient.
We used mixed models using nested random effects (village,
patient) [45] to assess the influence of factors on ECP and
rebound, adjusting as relevant for the following: gender, age at
start of each course (categorised), pre-course VBLL (for ECP), end-
course VBLL (for rebound), timing of the end-course VBLL
measurement relative to first DMSA dose, DMSA dose regimen,
whether it was the first course of DMSA, DMSA administration
method, and start-of-course haemoglobin.
In analysing the associations between treatment with a course of
DMSA and ECP, it was considered important to account for
variations in DMSA administration method and dose regimen.
These factors were not independent, as protocols and implemen-
tation practicalities for both changed over time as the intervention
progressed. In addition, the duration of TDS dosing as opposed to
BD dosing was based on pre-course VBLL (Table 2), so pre-course
VBLL would confound assessment of the role of dose regimen if
Figure 2. Flow chart of inclusion and exclusion of courses in analysis. *Protocol changeover dates given in Table 2 were strictly applied in
reviewing the data, even though implementation in the seven village clinics probably did not occur instantly. Accordingly, some data exclusions were
for courses commenced within a few days of a protocol changeover. 92% of exclusions for this reason would have been excluded because of one or
more of the other exclusion criteria, which were applied in sequence. EDTA, CaNa2EDTA.
doi:10.1371/journal.pmed.1001739.g002
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both were included as independent variables in the model of ECP.
Therefore, the primary multivariable model of interest using ECP
as the outcome variable was based on 2,262 chelation courses that
featured the most prevalent chelation dose regimen: 19 d of
treatment (7 d TDS + 12 d BD). A secondary model assessed
variations in dose regimen using (coincidentally also) 2,262 courses
administered by alternate-day DOT. A subanalysis of courses
commenced at VBLL $ 120 mg/dl on the 19-d TDS regimen
assessed the impact of DMSA at very high VBLLs. Because
changes in the protocol with respect to dose regimen and dose
administration method were highly correlated with calendar date,
the date of a course of chelation was not included as an
independent variable in the models. No allowance for multiple
testing was performed.
For categorical variables the largest group was used as the base
reference, except for haemoglobin, where ‘‘normal’’ was used as
the reference. Variables were added to the multivariable model if
they were significant in univariate regression at p ,0.1 or if they
were considered clinically or programmatically important. Final
multivariable models were selected using backward elimination. p-
Values were calculated for the strength of association of each
variable with the outcome using Wald tests. The DMSA
administration method categorical variable was assessed as
continuous (in order of decreasing frequency of DOT as shown
in the tables) to test for trend. Interaction was assessed where
plausible and when sufficient data were available in subgroups to
yield precise estimates. All observations were included in the
Table 3. Baseline characteristics.
Characteristic
Pre-Chelation{
(n=1,156 Children)
Pre-Course
(n=3,180 Courses)
Age at start
of course
0 to ,6 mo 48 (4%) 63 (2%)
$6 mo to ,1 y 128 (11%) 300 (9%)
$1 y to ,2 y 190 (16%) 689 (22%)
$2 y to ,3 y 115 (10%) 342 (11%)
$3 y to #5 y 675 (58%) 1,786 (56%)
Sex
Male 599 (52%) 1,638 (52%)
Female 557 (48%) 1,542 (48%)
VBLL (mg/dl)
45–64.9 709 (61%) 1,856 (58%)
65–79.9 68 (6%) 187 (6%)
80–119.9 295 (26%) 945 (30%)
120–199.9 69 (6%) 174 (5%)
200–345 15 (1%) 18 (1%)
Data are n (percent).
{First course with full data for each child, not all first-ever course.
doi:10.1371/journal.pmed.1001739.t003
Figure 3. Flow chart of children commencing chelation in period analysed, with inclusion and exclusion in analysis and death
outcomes. Lead was attributed as the primary cause of death where there was a high (.100 mg/dl) VBLL within 10 d before death, where there was
no other obvious cause, and where lead toxicity could not be excluded as a cause. Lead was attributed as a contributory cause where a serious
comorbidity was present (measles, bronchopneumonia, malaria, septicaemia, or severe malnutrition) but with a recent VBLL. 90 mg/dl. Deaths were
categorized as ‘‘no clear role of lead’’ where there was another obvious cause (e.g., fell into an open well, anaemic heart failure, or measles) and no
recent VBLL. 65 mg/dl. Reasons for not including in the study cohort were not finishing the chelation course (through defaulting or death before
end of course) or no VBLL recorded at end of course. *All died during first treatment course. {Two died during first treatment course.
doi:10.1371/journal.pmed.1001739.g003
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mixed regression models; courses with missing data (n= 23 [1%],
primarily haemoglobin missing) were dropped by the statistical
software as not being able to contribute to the model estimation.
To estimate how well the variation in the data was explained, we
fitted a linear regression, approximating the mixed model for 19-d
single-regimen courses, by including village as a variable and
adjusting for clustering by patient by using robust standard errors.
Standard regression diagnostics were performed using analysis of
residuals. Data were analysed using STATA 10.1 (StataCorp).
Results
A total of 3,180 DMSA treatment courses of 19 or 28 d
commenced between 1 June 2010 and 30 June 2011 were included
(Figure 2). Included courses were administered to 1,156 children,
nine of whom had died by end of June 2011. One death was likely
solely due to lead encephalopathy; eight children died from other
primary causes, but two of these children had had lead levels.
90 mg/dl within 10 d of death (Figure 3). Amongst children
excluded from the primary analysis, five additional deaths
occurred during the first chelation course with likely primary
cause of death listed as lead toxicity (most recent VBLL 216–
460 mg/dl), including two commenced on CaNa2EDTA. Another
three children died because of another primary cause but had had
lead levels. 90 mg/dl within 10 d of death. These eight are not
included in the treatment analysis as they did not have an end-
course VBLL or did not meet other inclusion criteria (Figure 3).
First treatment courses (882 courses) constituted 28% of those
analysed; the first administered course did not meet the inclusion
criteria for 274 children for whom later courses could be included.
66% of children had more than one course, with some receiving
up to 15 treatment courses of any length (median 3 courses,
interquartile range 1–4) during the 13 mo analysed. The
male:female ratio for the number of courses started was 1.06.
More than half of the patients were aged 3–5 y (Table 3). Pre-
course VBLLs ranged from 45 to 345 mg/dl (median 60,
interquartile range 52–92). 36% and 6% of courses were
commenced with a VBLL $80 mg/dl and $120 mg/dl, respec-
tively.
Of 19- or 28-d courses completed between June 2010 and end
June 2011, only 82% had both pre-course and end-course VBLLs
that were classified as valid measures for that treatment event
point. This was due to the logistical challenges of reaching villages
(e.g., during the rainy season, resulting in delayed blood tests), lack
of stock of laboratory test supplies due to high demand, and, in the
early months, challenges with maintaining adequately low ambient
temperature for laboratory equipment in the harsh environment.
Excluded courses without an end-course VBLL had a slightly
(2.4 mg/dl) but significantly (rank-sum p= 0.008) higher pre-
course VBLL than those with both tests recorded.
ECP after a DMSA course: Overview
For all 3,180 courses (Table 4), ECP had a geometric mean of
74.5% (95% CI 69.7%–79.7%) (Table 5), with a mean absolute
decrease of 22.3 mg/dl (95% CI 8.1–36.5) (Figure 4). At the end of
a single treatment course, ECP varied from 7% to 274%. Instances
in which ECP exceeded 100% occurred predominantly when the
pre-course VBLL was less than 120 mg/dl (Figure 5). At the end of
their most recent course, 71% of children had a VBLL lower than
their pre-chelation VBLL; for most children this was an interim
measure at the end of the analysis period but not the end of their
treatment intervention (Figure 6).
For 882 first-ever treatment courses that met inclusion criteria,
the geometric mean ECP was 68.0% (95% CI 59.2%–78.2%),
with a mean absolute decrease of 29.4 mg/dl (95% CI 8.8–50.0).
For 2,298 subsequent (after-first) courses, the mean ECP was
80.2% (95% CI 77.3%–83.3%), with a mean absolute decrease of
12.5 mg/dl (95% CI 10.5–14.5).
For all 19-d courses (n= 3,120) mean ECP was 75.2% (95% CI
70.5%–80.3%), with a mean absolute decrease of 22.2 mg/dl (95%
CI 7.1–37.3). The lowest mean ECP (38.8% [95% CI 32.4%–
46.4%]) was achieved in the 60 courses of 28-d duration
administered entirely on an inpatient basis. All outpatient
administration methods (fewer doses DOT) had a higher mean
ECP. The mean ECP for inpatients with all doses DOT was
47.7% (95% CI 39.7%–57.3%) compared with 79.3% (95% CI
3.8%–85.2%) for outpatient courses given as alternate-day DOT
(Table 5).
19-d Single-Regimen Courses
For 19-d courses using the 7 d TDS + 12 d BD regimen
(n= 2,262) (Table 6), the final adjusted model showed ECP was
significantly associated with age, pre-course VBLL, interval since
previous course, administration method, timing of end-course
VBLL measurement, and haemoglobin. After adjustment for the
other variables included in the final model, first treatment courses
were not associated with any difference in ECP compared with
subsequent courses. Gender was not associated with change in
ECP but was retained in the final model as a key demographic
factor. ECP was 12%–17% higher in children aged ,3 y than in
those aged 3–5 y (Table 6). Pre-course VBLL was strongly
associated with ECP: 0.54% lower ECP for every 1 mg/dl increase
in pre-course VBLL within the range 45 to ,120 mg/dl, with
geometric mean pre-course VBLL 60.5 mg/dl (95% CI 57.2–63.2).
For each extra chelation-free day since the end of the previous
course, there was a 0.05% larger decrease in ECP. ECP was lowest
if VBLL was measured immediately at the end of a treatment
course compared to a few days after a course ended. Low
haemoglobin at the start of a course was associated with a relative
increase (6.7%) in ECP compared to normal haemoglobin. Linear
regression including village and clustered by patient indicated that
the model explained approximately 26% (R2= 0.255) of the
variation in the data. Standard regression diagnostics indicated
that residuals were normally distributed. There was no evidence of
interaction between pre-course VBLL and administration method
(p= 0.11). Administration methods that offered greater opportu-
nity for DOT by clinic staff were associated with larger reductions
in ECP during a course (test of trend p ,0.001).
Influence of Dose Regimen during 19-d Courses
The relative ECP for different dose regimens was examined
within the subset of courses administered by alternate-day DOT
(n= 2,262). After adjustment for age, first course versus subse-
quent course, days since previous course ended, timing of end-
course VBLL measurement, and haemoglobin (all associations
similar to those in Table 6), the 19-d TDS regimen yielded an
18.6% lower ECP—and the 5 d TDS + 14 d BD regimen yielded
a 4.4% lower ECP—than the 7 d TDS + 12 d BD regimen. This
finding suggests that dosing three times a day for the whole course
might yield the greatest reduction in VBLL. However, differences
in ECP suggested by TDS versus BD dosing may instead just
reflect the influence of pre-course VBLL differences (in light of the
role of pre-course VBLL demonstrated in the model in Table 6).
The geometric mean pre-course VBLL was 140.9 mg/dl (95% CI
134.8–147.3) for 19-d TDS courses, 58.4 mg/dl (95% CI 58.3–
60.4) for 7 d TDS + 12 d BD, and 75.5 mg/dl (95% CI 66.6–85.6)
for 5 d TDS + 14 d BD, relative levels that are coherent with the
ECP differences.
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Courses Commenced with Very High VBLLs
The geometric mean ECP for 148 courses commenced at VBLL
$ 120 mg/dl using the 19-d TDS regimen was 67.8% (95% CI
61.7%–74.4%). A mixed model confined to these courses
commenced with high pre-course VBLL showed that after
adjustment for age and haemoglobin (associations consistent with
main model), three factors were strongly associated with ECP. A
first course was associated with lower ECP than a subsequent
course (221.8%, 95% CI 234.1% to 29.5%), a finding not seen
in the larger models that included initial VBLL values from 45 mg/
dl. An increase in the interval between chelation courses was
associated with a 0.7% per day (95% CI 21.1% to 20.3%)
decrease in ECP. Every 1 mg/dl increase in pre-course VBLL in
this subgroup was associated with a 0.20% (95% CI 20.33% to
20.07%) decrease in ECP.
The geometric mean ECP for 159 almost exclusively inpatient
courses of 19 or 28 d (.95% of course in hospital) was 47.7%
(95% CI 39.7%–57.3%) (Table 5), with a mean absolute decrease
of 56.2 mg/dl (95% CI 40.7–71.6). For 145 inpatient-only courses
that were also first-ever courses the decline was slightly greater,
yielding an ECP of 44.9% (95% CI 35.4%–56.8%). Modelling
indicated that the influence of pre-course VBLL on ECP was
attenuated in the subset of patients undergoing a first course of
DMSA administered entirely on an inpatient basis. In this subset
(n= 145, geometric mean pre-course VBLL 106.2 mg/dl, 95% CI
87.1–129.4), after adjustment for age, for every 1 mg/dl increase in
pre-course VBLL there was only a 0.09% decrease in ECP (95%
CI 0.02% to 0.16%; p= 0.014).
VBLL Rebound
In 2,444 pairs of tests that included a test at the end of a 19-d
course of any dose regimen and the subsequent test following an
interval without chelation (median 19 d, range 1–262), the
geometric mean (nested by village and patient) of the VBLL
rebound was 122.5% (95% CI 118.9%–126.3%), with 82% of tests
showing VBLL rebound above the end-course VBLL (Figure 7).
Factors significantly associated with higher rebound included
higher VBLL at the start and end of the course just taken, and
more chelation-free days between courses and tests. The largest
percentage change was with the VBLL at the end of the course:
the lower the absolute value of the end-course VBLL, the lower
the percent rebound (Table 7). Exclusion of very high rebound
outliers did not attenuate the strong associations in the model.
Adverse Events
There were no anecdotal reports of severe clinical adverse
events related to DMSA. One child developed pneumonia while
receiving DMSA via nasogastric tube. This was diagnosed
Table 4. Number of courses by dose regimen and administration regimen.
Regimen
.95% Course
in Hospital
50%–95% Course in
Hospital, Then
Outpatient
$80% Course
Outpatient
Daily DOT
Course via Outpatient
Mixed DOT (Daily then
Alternate Day)
$80% Course
Outpatient
Alternate-Day DOT
Total (Percent
of Total)
28 d BD 60 (100%) 0 0 0 0 60 (2%)
19 d TDS 27 (12%) 9 (4%) 86 (39%) 1 (0%) 98 (44%) 221 (7%)
7 d TDS + 12 d BD{ 72 (3%) 89 (4%) 414 (18%) 137 (6%) 1,573 (69%) 2,285 (72%)
5 d TDS + 14 d BD 0 0 0 0 614 (100%) 614 (19%)
Total 159 (5%) 98 (3%) 500 (16%) 138 (4%) 2,285 (72%) 3,180
Data are n (percent of regimen). Categories differentiate full DOT (here meaning entire course was taken in hospital) compared with various combinations of partial DOT
when a child was discharged mid-course to receive the remainder of the course in the community, either with daily or alternate-day DOT of one of the day’s doses and
the remainder administered by the caretaker at home.
{Courses in this row included in model in Table 6.
doi:10.1371/journal.pmed.1001739.t004
Table 5. Association of dose regimen and dose administration method with geometric mean ECP (expressed as percent).
Regimen
.95% Course
in Hospital
(n=159)
50%–95% Course
in Hospital, then
DOT (n=98)
$80% Course via
Outpatient Daily
DOT (n=500)
Course via Outpatient
Mixed DOT (Daily
then Alternate Day)
(n=138)
$80% Course via
Outpatient Alternate-
Day DOT (n=2,285)
Total (Percent of
Total) (n=3,180)
28 d BD (n= 60) 38.8%
(32.4%–46.4%)
— — — — 38.8% (32.4%–46.4%)
19 d TDS (n= 221) 55.5%
(46.2%–66.5%)
81.3%
(57.7%–114.6%)
78.4% (73.2%–83.9%) 95% 72.0% (66.3%–78.2%) 73.1% (69.5%–76.9%)
7 d TDS + 12 d BD
(n= 2,285)
49.6% (39.5%–
62.2%)
55.7%
(37.6%–82.5%)
76.0% (63.3%–91.3%) 75.0% (71.8%–78.3%) 83.9% (79.6%–88.4%) 78.3% (73.6%–83.3%)
5 d TDS + 14 d BD
(n= 614)
— — — — 74.6% (67.4%–82.6%) 74.6% (67.4%–82.6%)
Total (n= 3,180) 47.7% (39.7%–
57.3%)
61.6% (43.9%–86.3%) 76.4% (64.4%–90.7%) 75.1% (71.9%–78.4%) 79.3% (73.8%–85.2%) 74.5% (69.7%–79.7%)
Data are ECP (95% CI). See Table 4 for number of courses per cell.
doi:10.1371/journal.pmed.1001739.t005
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clinically on the basis of fever, hypoxia, and unilateral chest
crepitations on auscultation as there were no radiology services
available. The child had an AVPU (alert, voice, pain, unrespon-
sive) [46] score of U, and the pneumonia may have been
secondary to aspiration in a deeply unconscious child without
sufficient gag reflex, though this was not confirmed. Alternatively,
it may have represented a non-aspiration nosocomial pneumonia
in a critically ill child. The child was treated with oxygen, IV
ampicillin, and metronidazole and recovered. Three deaths in
children with an AVPU score of P or U receiving DMSA by
nasogastric tube (11% of 26 children) occurred in the first few days
of treatment with severe lead poisoning as the primary cause; these
patients were not included in the analysed courses as there was no
end-course VBLL (Figure 3).
The incidence of severe neutropenia (neutrophil count ,0.56
109/l) after any course of DMSA was low (0.4%) and was
comparable to that seen before commencement of DMSA (0%
severe neutropenia pre-chelation, 0.3% severe neutropenia before
any individual course). Of six children with severe neutropenia at
the start of a course, three had normal neutrophil counts and
three no result when the end-course VBLL was measured, but
nine of the ten children with severe neutropenia at the end of a
course did not have a result recorded for the start of that course.
There were no recorded cases of severely elevated ALT (.1,000
U/l) either in chelation-naı¨ve patients or after DMSA had been
started. Moderately elevated ALT (100.1–1,000 U/l) was present
in 1.0% of chelation-naı¨ve children (range 4–256 U/l), increasing
slightly to 1.8% after one course of DMSA, and staying constant
at 2.4% after multiple courses (ALT range 3.2–498 U/l).
Doubling or more of ALT during a course of DMSA occurred
in 123 courses (of 2,588 with data, 4.8%). No clinical laboratory
result required discontinuation of further chelation treatment in
any child.
Discussion
We report the largest cohort, to our knowledge, of children
treated with chelation therapy for severe lead poisoning to date.
Our experience demonstrates that oral DMSA may be suitable for
use as a single agent in patients with severe lead poisoning,
particularly in resource-limited and/or remote settings. The
establishment of chelation treatment for lead-poisoned chil-
dren—in parallel with an environmental remediation programme
to reduce ongoing exposure—in villages in rural northern Nigeria
was associated with a large and rapid decrease in the number of
deaths due to lead poisoning. Only six deaths thought to be solely
due to lead poisoning occurred during the 13-mo period analysed,
compared with over 400 fatalities in the three preceding months
(Figure 3). The primary end point of interest in our analysis was
quantitative reduction of VBLL achieved during a course of oral
DMSA chelation, expressed as ECP. Lower VBLLs are associated
with fewer clinical and sub-clinical features of lead poisoning, and
VBLLs $80 mg/dl are associated with encephalopathy [16]. A
clinically desirable lower value of ECP was more strongly
associated with first-ever courses of chelation than with subsequent
courses, with inpatient than with outpatient courses, and with a
greater degree of DOT. In a multivariable regression analysis of
outpatient chelation courses, ECP was lower with older age,
higher pre-course VBLL, greater level of DOT, and higher
haemoglobin. The magnitude of rebound in VBLL after
completion of a course was positively correlated with pre-course
VBLL. No serious adverse drug effects attributed to oral DMSA
were observed. A moderate increase in ALT that did not require
discontinuation of chelation occurred in ,1.5% of children.
Paediatric lead encephalopathy not treated with chelation has
historically been associated with a case mortality rate of
approximately 65% [47]. Use of enhanced supportive care and
Figure 4. Geometric mean (95% CI) of absolute pre-course and end-course VBLL for all courses nested by village and patient, by
treatment dose regimen.
doi:10.1371/journal.pmed.1001739.g004
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the parenteral chelating agents CaNa2EDTA and dimercaprol
reduced this to ,5% by the 1960s [48]. In the present cohort,
remediation, supportive care, and chelation resulted in an overall
all-cause mortality in all children commencing any chelation of
1.5% (20/1,307; Figure 3). The case mortality rate in severe
paediatric lead poisoning was ,2.5% among 479 children (379 in
study cohort; Table 3) who started chelation with initial VBLL $
80 mg/dl. This rate is based on a conservative estimate of 11 (six
primary, five possible contributory) lead poisoning deaths in this
group (Figure 3). This is a marked decrease from the 48%
mortality in probable or suspected child cases documented until
mid-May 2010, before the chelation programme was initiated
[16].
Across the entire study period, 71% of the children experienced
a net reduction in VBLL and 29% a net increase in VBLL after 1–
15 courses. These values reflect children at all stages of chelation
during the study period, many of whom continue to receive
treatment as part of the ongoing medical programme. The overall
mean ECP value of 68.0% (corresponding to a decrease in VBLL
of 32%) for first-ever courses of DMSA was higher than that
observed in other studies of paediatric lead chelation, in which
ECP values of 19% to 60% were reported (Table 8) [39,49,50,51].
By comparison, the subset of children who received their first
course as inpatients experienced a geometric mean ECP of 44.9%.
This latter value, similar to that reported in other studies in
resource-rich countries, likely reflects the impact of assured
medication compliance in a lead-free environment.
Nearly one-third of the children in this study finished the 13-mo
study period with a VBLL that exceeded their initial pre-chelation
VBLL. This suggests that despite remediation and community
education, outpatient re-exposure to environmental lead contam-
ination was widespread. The implementation of safer mining
practices and mitigation of some re-exposure pathways, such as
‘‘take-home exposure’’ from parents engaged in high-risk artisanal
mining activities, were challenging for the community. Additional
potential pathways of lead re-exposure were not quantified, such
as potential contamination of the food supply and the use of
lead-contaminated mud bricks for housing. The value of ECP
achieved with outpatient courses of chelation, which constituted
most of the courses in this study, would likely have been better if all
potential sources of re-exposure to lead could have been mitigated.
Our finding of an incremental decrease in ECP as pre-course
VBLL increased was unexpected. Pharmacokinetic studies have
suggested that the in vivo conversion of DMSA to an active
chelating moiety, and its subsequent renal clearance, may be
diminished in children with significant lead poisoning, so a higher
ECP might be expected in children with higher VBLLs [52,53]. In
a series of 17 adults with pre-course VBLLs between 50 and
140 mg/dl, higher pre-course VBLL was correlated with a higher
ECP after 5 d of DMSA treatment [25]. One potential
Figure 5. Unadjusted end-course VBLL as a percentage of pre-course VBLL (ECP) by pre-course VBLL (mg/dl) (n=3,180).
doi:10.1371/journal.pmed.1001739.g005
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explanation for our findings is that in patients who present with
high initial VBLLs, DMSA results in more efficient mobilisation
and excretion of labile blood lead pools than in those starting
chelation at a lower VBLL. It is also possible that children with
higher pre-course VBLLs may have been less active and
ambulatory, and therefore sustained less concomitant re-exposure
to lead during each chelation course. This effect of possible
re-exposure may have persisted even after adjustment for location
of treatment (Table 6). As may be seen in Figure 5, some chelation
courses initiated with a pre-course VBLL of less than approxi-
mately 120 mg/dl were associated with an ECP of .100% (i.e., an
end-course VBLL greater than the pre-course VBLL). This finding
is not generally observed in the absence of re-exposure.
In patients with VBLL$ 120 mg/dl, it was notable that the ECP
achieved by the first course was substantially better than that
achieved by subsequent courses. This finding has also been observed
with lead chelation of severely poisoned patients treated with
CaNa2EDTA [12,54,55]. Similarly, within courses of chelation with
CaNa2EDTA and DMSA, the largest change in VBLL and urinary
lead excretion is usually observed during the first 1–2 d of treatment
[26,27,55,56]. Overall, this pattern is consistent with a mobilisation
capacity of chelating agents that is most efficient for labile lead pools
that are less tightly bound to cellular targets.
For each extra day between 19-d courses there was a 0.05%–
0.20% lower ECP at the end of the subsequent course (depending
on subset analysis), such that a 30-d gap between courses was
estimated to result in an additional decrease in ECP on the
subsequent course of approximately 2%–6%. This suggests an
increased pharmacodynamic effect of DMSA in mobilising lead as
the interval between courses increases. Graziano et al. showed that
patients who received no further chelation after a 5-d course of
DMSA 1,050 mg/m2 per day rebounded to a higher VBLL 1 wk
post-course than those who received either 350 mg/m2 or
700 mg/m2 of DMSA per day over the subsequent 14 d [26].
Further research is needed to determine the optimal chelation-free
period between courses, as the clinical impact of a given VBLL
without chelation for a longer period should be weighed against
potentially achieving a larger subsequent VBLL decrease. There
are also potential cost savings if the same long-term impact on
VBLL can be achieved with greater spacing between courses
without the risk of increased neurological morbidity.
There were only 60 courses of the 28-d regimen included in our
analysis, compared with 3,120 19-d courses. The 28-d inpatient
courses were given at a very early emergency stage of the
programme to some of the most severely poisoned children.
Because 19-d course regimens were selected based on pre-course
Figure 6. Histogram of latest VBLL during the entire study period as a percentage of pre-chelation VBLL per child. As the role of
repeated courses on combined overall change cannot be extracted, change includes effect of all courses (e.g., 5-d and CaNa2EDTA courses). This does
not represent the end of treatment in most cases, but rather an interim measure at the end of the study period.
doi:10.1371/journal.pmed.1001739.g006
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(and initially day 7) VBLL, the influence of pre-course VBLL and
various treatment regimens could not be dissected to ascertain
whether the apparently greater impact of the 28-d regimen on
ECP was independent of pre-course VBLL and other factors. This
would be an interesting direct comparison for future study. Thus,
while the decreases in ECP were greater with the 28-d regimen, we
do not conclude that there is sufficient evidence to support its
adoption in place of 19-d regimens.
With the most widely used dose regimen (7 d TDS + 12 d BD),
administration of 80% of the course by daily DOT resulted in an
ECP of 76.0%; this increased to 83.9% when alternate-day DOT
was instituted (see Table 5), possibly because of decreased
medication adherence for the doses administered at home by the
caretaker. This protocol change was nonetheless judged necessary
by the expert advisory group based on the limited capacity of the
outpatient clinic in the face of an increasing caseload, and the
requests of parents who found it difficult to return to the clinic on a
daily basis with their child. The expert advisory group considered
that a failure to switch to alternate-day DOT might have resulted
in many parents abandoning chelation treatment altogether. An
MSF health promotion and community mobilisation team
continue to work in Zamfara to support outpatient treatment
adherence.
We noted an inverse relationship between haemoglobin
concentration and ECP (Table 4), similar to the smaller decrease
in VBLL in iron-deficient children described by Ruff et al.,
although that study used CaNa2EDTA as the chelating agent [57].
Anaemia in the setting of lead intoxication is associated with an
increased percentage of lead in the plasma fraction of blood
[58,59]. Higher plasma lead may be associated with greater
loading of lead into the soft tissues and skeleton, reducing the
impact of chelation on VBLL. The adjusted model that included
haemoglobin, in addition to age and DMSA dose factors,
explained about 26% of the variation in ECP (Table 6),
Table 6. Mixed model of ECP using nested random effects for a 19-d (7 d TDS + 12 d BD) DMSA chelation course (n= 2,285 in
unadjusted analysis; n= 2,262 in adjusted analysis limited to patients with data on all covariates).
Characteristic N*
Unadjusted
Estimate (95% CI)
Adjusted
Estimate{ (95% CI) p-Value (Adjusted Model)
Age at start of each course ,0.001
0 to ,6 mo 38 3.7% (24.4%, +11.8%) 12.4% (+4.8%, +19.9%)
6 to ,12 mo 211 10.6% (+6.9%, +14.4%) 14.7% (+10.9%, +18.4%)
1 to ,2 y 398 11.7% (+8.7%, +14.7%) 17.1% (+14.0%, +20.3%)
2 to ,3 y 226 10.4% (+6.6%, +14.1%) 11.8% (+7.9%, +15.6%)
3 to #5 y 1,412 Referent Referent
Sex 0.44
Male 1,162 Referent Referent
Female 1,123 20.70% (23.0%, +1.6%) 20.90% (23.2%, +1.4%)
Course number 0.14
First 540 28.6% (211.0%, 26.1%) 22.1% (25.0%, +0.7%)
Second or later 1,745 Referent Referent
Pre-course VBLL (per 1 mg/dl) 2,285 20.65% (20.70%, 20.60%) 20.54% (20.60%, 20.49%) ,0.001
Days since last course ended (per day) 2,285 0.07% (+0.03%, +0.12%) 20.05% (20.10%, 20.01%) 0.017
Administration method ,0.001
.95% course in hospital 72 231.9% (237.6%, 226.3%) 215.2% (220.8%, 29.6%)
50%–95% of course in hospital, then outpatient 89 221.8% (226.9%, 216.6%) 212.1% (217.2%, 27.1%)
$80% course via outpatient daily DOT 414 215.0% (217.8%, 212.3%) 28.4% (210.9%, 25.8%)
Course via outpatient mixed DOT
(daily then alternate day)
137 29.7% (213.9%, 25.5%) 28.2% (212.2%, 24.2%)
$80% course via outpatient alternate-day DOT 1,573 Referent Referent
Timing of end-course test, relative to start` 0.004
Day 17–19 1,614 Referent Referent
Day 20–26 645 4.4% (+2.1%, +6.7%) 3.2% (+1.2%, +5.2%)
Day 27–29 24 9.7% (20.4%, +19.8%) 6.7% (22.0%, +15.4%)
Haemoglobin (pre-course) ,0.001
Normal 895 Referent Referent
Low 1,355 6.7% (+4.5%, +8.9%) 6.6% (+4.5%, +8.6%)
High 14 210.4% (223.5%, +2.7%) 27.9% (219.1%, +3.4%)
A positive value of ECP indicates an increase in VBLL; a negative value of ECP indicates a decrease in VBLL. DOT by clinic staff; non-DOT doses administered by caretaker.
*Total patients in unadjusted analyses= 2,285. Final model (n= 2,262) excludes those with missing data (1%).
{Adjusted for all other variables shown in the table.
`An end-course VBLL was accepted if up to 2 d before and up to 10 d after last dose of DMSA.
doi:10.1371/journal.pmed.1001739.t006
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which—not unexpectedly, given the complex setting of the
study—indicates that other relevant but unmeasured variables
exist.
Our findings indicate that in obtunded children with lead
encephalopathy, oral administration of DMSA via nasogastric
tube was feasible and associated with a reduction in VBLL. It
carries the risk of aspiration, although only one possible case of a
complication arising from aspiration was documented among 26
(14 in analysed courses, 12 in excluded courses) courses of
DMSA administered by nasogastric tube in this cohort. Three of
18 deaths in children commenced on DMSA occurred in
children receiving it by nasogastric tube; these incomplete
courses were not included in the ECP analysis. In developed
countries, children with severe lead encephalopathy are treated
in intensive care units with CaNa2EDTA singly or in combina-
tion with dimercaprol. The experience in the present cohort
suggests that nasogastric administration of DMSA was an
acceptable alternative, which is particularly pertinent to
Figure 7. VBLL rebound by the number of days between end-course VBLL and next test. VBLL rebound is VBLL at the next test after the
end of a 19-d course and a chelation-free period, as a percentage of end-course VBLL.
doi:10.1371/journal.pmed.1001739.g007
Table 7. Mixed model of VBLL rebound following a course of chelation (nested random effects; n= 2,444).
Course Characteristic Unadjusted Estimate (95% CI) Adjusted Estimate (95% CI) p-Value
VBLL at start of course (per 1 mg/dl) 0.34% (+0.26%, +0.43%) 0.73% (+0.65%, +0.81%) ,0.001
VBLL at end of course (per 1 mg/dl) 21.41% (21.56%, 21.27%) 21.95% (22.10%, 21.80%) ,0.001
Interval since prior chelation course (per day) 20.20% (20.28%, 20.13%) 20.15% (20.21%, 20.08%) ,0.001
Days from when this course ended to when the ‘‘next’’ VBLL
was measured (per day)
0.23% (+0.13%, +0.33%) 0.22% (+0.13%, +0.30%) ,0.001
Constant coefficient 167.06 (157.08, 177.04) ,0.001
VBLL rebound is VBLL at the next test after the end of a 19-d course as a percentage of end-course VBLL.
doi:10.1371/journal.pmed.1001739.t007
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resource-limited and/or remote settings. Optimally, depending
on the resource setting, an unconscious child would be
intubated, diminishing the risk of aspiration from nasogastric
administration of DMSA.
The mild rise in ALT observed during DMSA chelation is
consistent with other reports [24]. No ALT exceeded 500 U/l, and
no overt hepatic dysfunction was observed. Drug-induced neutro-
penia was not detected, and there was no adverse effect of chelation
on creatinine. Adverse clinical symptoms sometimes associated with
DMSA therapy in other reports, including gastrointestinal discom-
fort and mild rash [25], were not systematically documented. Severe
adverse drug reactions, such as anaphylaxis or mucocutaneous drug
eruptions, did not occur. Overall, the acceptable safety profile of
oral DMSA chelation in this study was similar to that reported in
other studies of lead chelation.
Limitations
This is a retrospective analysis of clinical data with the associated
limitations. No allowance for multiple testing was performed; false-
positive results are possible. Analyses were nested by village of
residence to account somewhat for unmeasured variables related to
environmental exposure; however, there were undoubtedly other
variables that may have influenced change in VBLL. The use of
point-of-care testing equipment rather than ICPMS mildly decreased
the accuracy of VBLLs. Our primary measure of DMSA effectiveness
was ECP, which required an end-course VBLL within the defined
timeframe, resulting in exclusion of five deaths during the first DMSA
course, a possible source of bias. Another six deaths were in children
with no courses meeting inclusion criteria. Exclusion of these deaths
from 3,180 courses analysed is unlikely to have affected the primary
outcome. To mitigate these exclusions, in our calculation of ,2.5%
mortality in severely poisoned children (initial VBLL $ 80 mg/dl)
during the period studied we conservatively included all deaths
considered caused or contributed to by lead poisoning (n= 11) in
children who commenced any form of chelation.
Conclusion
In this retrospective analysis of an emergency intervention,
oral DMSA as a single agent was a pharmacodynamically
effective chelator for children with severe lead poisoning, even
when administered to obtunded encephalopathic children by
nasogastric tube. A lower end-course VBLL was associated with
higher pre-course VBLL, a longer interval between chelation
courses, and chelation administered in the inpatient setting.
The reduction in VBLL achieved by courses of oral DMSA
chelation that were entirely or predominantly inpatient was
comparable to that observed in previously published clinical
trials of oral DMSA or IV CaNa2EDTA. Re-exposure to
environmental lead contamination likely influenced the atten-
uated decline in VBLL associated with outpatient DMSA
chelation. Decreased medication adherence is likely to have
Table 8. Paediatric lead chelation: ECP as a function of drug regimen and dose administration method.
Study Drug Dose Regimen
Drug Administration
Method
Number of
Treatment
Courses
Mean Pre-
Course VBLL
(mg/dl) ECP
Chisolm
(1968) [48]
CaNa2EDTA (i.m.) +
dimercaprol (i.m.)
12.5 mg/kg q 4 h6 72 h and
4 mg/kg q 4 h6 72 h
Inpatient 8 272 19%
Chisolm
(1968) [48]
CaNa2EDTA (i.m.) 12.5 mg/kg q 4 h6 72 h Inpatient 7 163 47%
Chisolm
(1990) [49]
CaNa2EDTA (i.m.) 500 mg/m
2 BD6 5 d Inpatient 18 55 60%
Graziano et al.
(1992) [26]
CaNa2EDTA (IV) 500 mg/m
2 BD6 5 d Inpatient 4 54 55%
Graziano et al.
(1992) [26]
DMSA (po) 350 mg/m2 TDS6 5 d
+ 350 mg/m26 15 d
Inpatient (5 d) then
outpatient (15 d, no DOT)
6 52 50%
Liebelt et al.
(1994) [39]
DMSA (po) 10 mg/kg TDS6 5 d
+ 20 mg/kg BD6 14 d
Outpatient (no DOT) 7 51 42%
Liebelt et al.
(1994) [39]
DMSA (po) 10 mg/kg TDS6 5 d
+ 20 mg/kg BD6 14 d
Outpatient (no DOT) 23 31 40%
Chisolm
(2000) [50]
DMSA (po) 350 mg/m2 TDS6 5 d
+ 350 mg/m2 BD6 21–23 d
Inpatient and outpatient 66 37 35%
TLC Trial Group
(1998; 2000)
[28,51]
DMSA (po) 350 mg/m2 TDS6 7 d
+ 350 mg/m2 BD6 19 d
Outpatient (no DOT) 396 26 57%
Current study DMSA (po) 10 mg/kg TDS6 19 d; or
10 mg/kg6 7 d
+ 10 mg/kg BD6 12 d; or
10 mg/kg BD6 28 d
Inpatient (.95% course as
inpatient)
159 101 48%
Current study DMSA (po) 10 mg/kg TDS6 19 d;
or 10 mg/kg TDS6 7 d
+ 10 mg/kg BD6 12 d; or
10 mg/kg TDS6 5 d
+ 10 mg/kg BD6 14 d
Outpatient (.80% as
outpatient) with
alternate-day DOT
2,285 62 79%
po, per os (orally); i.m., intramuscular; q, every.
doi:10.1371/journal.pmed.1001739.t008
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occurred in outpatient settings and may also have diminished
the impact of chelation.
Although children with severe lead poisoning usually require
multiple courses of DMSA chelation, the most desirable time interval
between courses requires further investigation. This experience with
basic supportive care and chelation in a large paediatric cohort adds
significantly to the evidence base for clinical management of epidemic
lead poisoning, particularly in resource-poor settings.
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Editors’ Summary
Background. Lead, a toxic metal that occurs naturally in the
earth’s crust, is now present throughout the environment
because of human activities. For many years, lead was added
to paint and gasoline and used in solder for water pipes. In
addition, the mining, smelting, and refining of some metallic
ores releases lead into the environment. Inhalation of
contaminated air, consumption of contaminated food and
water, and contact with dust that contains lead raises venous
blood lead levels (VBLLs) and causes many health problems,
particularly in children. Children who ingest large amounts of
lead can develop anemia, muscle weakness, kidney damage,
and life-threatening encephalopathy (brain swelling). Al-
though fatal lead poisoning is now rare in resource-rich
countries, it nevertheless remains a major global health
problem. Over a three-month period in early 2010, for
example, about 400 young children died in Zamfara State,
Nigeria, from unexplained, intractable fits. By May 2010, it
was clear that recently expanded gold mining had caused
widespread environmental lead contamination in the region,
and an environmental management program was begun to
reduce lead levels in the surface soils.
Why Was This Study Done? In response to the lead
poisoning outbreak, the not-for-profit organization Me´decins
Sans Frontie`res (MSF) began a medical management
program to reduce VBLLs that included treatment with the
oral chelation agent dimercaptosuccinic acid (DMSA). Che-
lation agents bind metal ions and facilitate their removal
from the body, thereby reducing the likelihood of lead
moving from the blood to the brain. Lead encephalopathy
has been commonly treated by injecting another chelator
called CaNa2EDTA, but the discovery of more than 1,000
cases of childhood lead poisoning in rural villages in Nigeria
meant that MSF needed a chelation approach that could be
applied rapidly in a remote resource-limited setting. Addi-
tionally, although CaNa2EDTA has been in common use for
severe lead poisoning for longer than DMSA, and is
commonly recommended in guidelines, the evidence base
does not support one treatment as superior. Here, in a
retrospective analysis of MSF program data, the researchers
evaluate the changes in VBLLs before and after courses of
oral DMSA treatment in children aged five years and below
living in Zamfara to gain new insights into this understudied
treatment for severe childhood lead poisoning.
What Did the Researchers Do and Find? The researchers
measured VBLLs before and after treatment with DMSA in
1,156 children (inpatient and outpatient) with high amounts
of lead in their blood who underwent one or more courses of
chelation treatment lasting 19 or 28 days by calculating each
child’s end-course VBLL as a percentage of the child’s pre-
course VBLL (ECP). Considering all the treatment courses
given between June 2010 and June 2011, the mean
(average) ECP was 74.5%. That is, on average, VBLLs
measured at the end of treatment courses were reduced
by a quarter compared to VBLLs at the start of treatment
courses. Among 159 inpatient courses of DMSA, the ECP was
47.7% (a halving of pre-course VBLLs). The ECP after 19-day
courses was lower in older children, after first-ever courses,
after courses with a longer interval since a previous course,
after courses that included more directly observed doses
(DMSA given in the presence of a health-care worker), and in
children with higher pre-course VBLLs. Nine of the children
included in this analysis died during the study period; lead
poisoning was probably involved in three of these deaths.
Importantly, no clinically severe adverse effects related to
DMSA were seen during the study period, and no laboratory
findings were recorded that required treatment discontinu-
ation.
What Do These Findings Mean? Because many changes
were made to the treatment given to the affected children in
Zamfara during the study period and because no informa-
tion is presented here on clinical outcomes, these findings
cannot be used to reach any definitive conclusions about the
effectiveness or safety of oral DMSA as a treatment for lead
poisoning in young children. However, these findings show
that chelation was associated with a large reduction in the
death rate among probable or suspected cases of childhood
lead poisoning in Zamfara and provide new information
about oral chelation that may help agencies such as MSF
provide urgent treatment for lead poisoning in resource-
limited settings where intravenous chelation is not feasible.
Moreover, the finding of a lower ECP after inpatient
treatment courses compared to after outpatient courses
suggests that re-exposure to lead and non-adherence to
treatment may have influenced the impact of outpatient
treatments. Thus, it is essential that medical management of
lead poisoning in resource-limited settings be accompanied
by environmental remediation and that efforts are made to
support adherence to treatment in the community by
implementing directly observed treatment wherever possi-
ble.
Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001739.
N A related PLOS ONE Research Article by Greig et al.
provides information about the association between
VBLLs and neurological features in children affected by
the acute lead poisoning outbreak in Zamfara
N MSF provides information about the lead poisoning
crisis in Zamfara State
N Human Rights Watch, an international organization
that works to uphold human dignity and advance the
cause of human rights for all, also provides informa-
tion about lead poisoning in Zamfara State, including
photographs and a video
N Tox Town, an interactive site about environmental
health concerns from the US National Library of
Medicine, provides information on exposure to lead
(in English and Spanish)
N The US Environmental Protection Agency provides
information on lead and lead poisoning (in English and
Spanish)
N The US Centers for Disease Control and Prevention
provides information about lead in the environment
and about its lead poisoning prevention program
N MedlinePlus provides a list of links to further
information about lead poisoning (in English and
Spanish)
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